Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Healthy Subjects

Next Previous
Trial Profile

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Petesicatib (Primary)
  • Indications Unspecified
  • Focus Pharmacodynamics
  • Sponsors Roche

Most Recent Events

  • 12 Feb 2021 Data from two studies (NCT02295332 [SAD] & NCT02521610 [MAD])) was used for pharmacokinetic analysis, published in the British Journal of Clinical Pharmacology.
  • 01 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
  • 17 Aug 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top